Prosecution Insights
Last updated: May 29, 2026

Examiner: RAMOS LEWIS, JOSMALEN MILAGROS

Tech Center 1600 • Art Units: 1621

This examiner grants 54% of resolved cases

Performance Statistics

54.1%
Allow Rate
-5.9% vs TC avg
89
Total Applications
+20.8%
Interview Lift
1032
Avg Prosecution Days
Based on 61 resolved cases, 2023–2026

Rejection Statute Breakdown

0%
§101 Eligibility
7.5%
§102 Novelty
86.7%
§103 Obviousness
3.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19313605 TOPICAL OCULAR DELIVERY OF CROMAKALIM Non-Final OA MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
18594178 Chlorthalidone Compositions And Methods Final Rejection Nivagen Pharmaceuticals, Inc.
19216569 SALT AND CRYSTAL FORM OF A FAK INHIBITOR Final Rejection Amplia Therapeutics Limited
19067074 COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER Final Rejection GSKB Pharmaceuticals, LLC
18991922 COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES Final Rejection ARIBIO CO., LTD.
17396292 GREEN POLYETHYLENE WAX FOR HOT MELT ADHESIVES, COATINGS, AND COSMETICS Final Rejection Braskem S.A.
17436882 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE Final Rejection University of Virginia Patent Foundation
17599210 METHODS FOR THE TREATMENT OF KELOID, HYPERTROPHIC SCARS AND/OR HYPERPIGMENTATION DISORDERS Non-Final OA ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
17436042 COMPOSITION COMPRISING AN ANTI-OXIDANT TO PRESERVE CORNEAL TISSUE Final Rejection University of lowa Research Foundation
18031103 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS Non-Final OA University College Cardiff Consultants Limited
17427949 METHODS AND COMPOUNDS FOR INHIBITION OF INACTIVATION OF VOLTAGE-GATED SODIUM CHANNELS Non-Final OA SIMON FRASER UNIVERSITY
17936058 METHOD FOR REDUCING LUNG INFLAMMATION Final Rejection Respirion Pharmaceuticals Pty Ltd
17274773 Use of Casein Kinase 1 Inhibitors For Treating Vascular Diseases Non-Final OA Qanatpharma AG

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month